Inovio Pharmaceuticals, Inc. (INO) is a publicly traded Healthcare sector company. As of May 21, 2026, INO trades at $1.24 with a market cap of $100.37M and a P/E ratio of -0.69. INO moved +2.46% today. Year to date, INO is -22.64%; over the trailing twelve months it is -42.25%. Its 52-week range spans $1.03 to $6.04. Analyst consensus is buy with an average price target of $4.50. Rallies surfaces INO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own INO include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Inovio Pharmaceuticals, Inc..
| Metric | Value |
|---|---|
| Price | $1.24 |
| Market Cap | $100.37M |
| P/E Ratio | -0.69 |
| EPS | $-1.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.04 |
| 52-Week Low | $1.03 |
| Volume | 88.06K |
| Avg Volume | 0 |
| Revenue (TTM) | $65.34K |
| Net Income | $-84.95M |
| Gross Margin | 0.00% |
2 analysts cover INO: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.50.